Ignite Creation Date:
2025-12-25 @ 12:10 AM
Ignite Modification Date:
2026-03-13 @ 12:52 PM
Study NCT ID:
NCT01251458
Status:
COMPLETED
Last Update Posted:
2016-09-28
First Post:
2010-12-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Hepatocellular Carcinoma (HCC)_Torisel_
Sponsor:
Chinese University of Hong Kong
Organization:
Study Overview
Official Title:
Phase I/II Study of Temsirolimus (Torisel®) as Novel Therapeutic Drug for Patients With Unresectable Hepatocellular Carcinoma (HCC)- A Correlative Study With Stathmin Over-expression
Status:
COMPLETED
Status Verified Date:
2016-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase I/II study to evaluate dose limited toxicity and efficacy of Torisel
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: